PTGX

PTGX

Last Updated:

Q3'20

Protagonist Therapeutics

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Our platform enables us to discover peptides in a de novo fashion with the desired degree of potency, specificity and selectivity, and also engineer oral stability with specific peptidomimetic and chemical modifications. We have successfully utilized this platform to discover PN-943 and PTG-200 which are oral, GI-restricted peptides for inflammatory bowel diseases (IBD), as well as PTG-300, an injectable peptide for rare blood disorders.

Cash

$194M

Burn Rate (Qtr)

-$7.8M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

PN-943 (α4β7-Integrin Antagonist)

Ulcerative Colitis (UC)

Phase 2 (Data)

TBA

PTG-300 (Hepcidin Mimetic)

Polycythemia Vera (PV)

Phase 2 (Data)

Q4 2020

PTG-200 (IL-23R Antagonist)

Crohn's Disease

Phase 2 (Data)

2021

PTG-300 (Hepcidin Mimetic)

Hereditary Hemochromatosis (HH)

Phase 2 (Data)

2021

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon